rs2908004 — WNT16 Gly82Arg

Missense variant in WNT16 that substitutes glycine for arginine at position 82, reducing cortical bone mineral density and increasing fracture risk

See your personal result for WNT16

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

WNT16 Gly82Arg — A Missense Variant That Weakens Cortical Bone

Your bones are constantly being broken down and rebuilt. At the heart of that process in cortical bone11 cortical bone
the dense outer shell that forms 80% of the skeleton and provides most of its mechanical strength sits the WNT16 protein — a signaling molecule secreted by bone-forming cells that keeps bone-resorbing cells in check. The rs2908004 variant introduces a single amino acid change (glycine to arginine at position 82) in WNT16 that impairs this regulatory function. Carriers of the G allele at this position tend toward thinner cortical bone, lower bone mineral density at fracture-prone sites, and elevated lifetime fracture risk. Unlike the neighboring intronic variant rs3801387 that influences WNT16 expression levels, rs2908004 directly alters the WNT16 protein structure.

The Mechanism

WNT16 is expressed predominantly by osteoblasts — bone-forming cells lining cortical bone surfaces22 expressed predominantly by osteoblasts — bone-forming cells lining cortical bone surfaces. It suppresses osteoclast (bone-resorbing cell) formation through two parallel pathways: directly inhibiting osteoclast progenitor differentiation via a non-canonical Wnt pathway33 non-canonical Wnt pathway
a signaling branch independent of the classic beta-catenin cascade, and indirectly through upregulating osteoprotegerin (OPG) — a decoy receptor for the osteoclast-activating signal RANKL. The net effect is preserved cortical thickness and reduced endocortical porosity.

The Gly82Arg substitution replaces a small, flexible glycine residue with a bulky, positively-charged arginine at position 82 in the WNT16 protein. Glycine residues at structural turning points in proteins are often critical for proper folding; their replacement frequently alters protein conformation and interaction with binding partners. Position 82 lies within the cysteine-rich domain (CRD)44 cysteine-rich domain (CRD)
the domain responsible for binding to WNT receptors (Frizzled family) and co-receptors; essential for signal transduction, the functional core of WNT ligands. Disrupting CRD geometry is a well-documented mechanism by which WNT family missense variants reduce signaling activity, consistent with the observed association between the G allele and lower BMD.

The Evidence

The definitive evidence for rs2908004 comes from a landmark GWAS meta-analysis by Zheng et al. (2012)55 landmark GWAS meta-analysis by Zheng et al. (2012) spanning 5,878 European subjects across multiple cohorts. The G allele at rs2908004 was associated with a −0.16 SD reduction in forearm BMD per allele (P = 1.2×10⁻¹⁵ — far exceeding genome-wide significance thresholds). Forearm BMD reflects cortical bone at the distal radius, one of the most common fragility fracture sites. The same study found a forearm fracture OR of 1.22 per G allele (P = 4.9×10⁻⁶).

García-Ibarbia et al. (2013)66 García-Ibarbia et al. (2013) studied 1,083 Spanish individuals and found rs2908004 associated with femoral neck BMD (average difference 35 mg/cm²; p = 0.00037), calcaneal ultrasound parameters (p = 0.00004), and femoral neck buckling ratio (p = 0.0007) — a geometric measure of fracture susceptibility. Among individuals under 80 years old, protective genotypes were significantly underrepresented in hip fracture patients (OR 0.50 for the protective genotype).

Age of study matters: Correa-Rodríguez et al. (2016)77 Correa-Rodríguez et al. (2016) demonstrated that rs2908004 influences broadband ultrasound attenuation (BUA)88 broadband ultrasound attenuation (BUA)
a quantitative ultrasound parameter that measures bone density and microarchitecture at the heel without radiation exposure even in young adults (mean age 20, n=575; p = 0.001). This positions the variant as a determinant of peak bone mass acquisition, not just age-related bone loss — making early intervention particularly meaningful.

The largest population study, the Taiwan Biobank analysis (Wu et al. 2022)99 Taiwan Biobank analysis (Wu et al. 2022) with 10,942 participants, confirmed a 35% lower osteoporosis risk in those with GA or AA genotypes compared to GG (OR 0.651; 95% CI 0.544–0.780). Importantly, the interaction between rs2908004 genotype and BMI was statistically significant (p = 0.0148), with underweight GG individuals facing particularly elevated risk (OR 7.66 vs normal-weight GG).

Practical Actions

The consistent finding across European and East Asian populations is that the G allele impairs WNT16-mediated osteoclast suppression, translating to thinner cortical bone and higher fracture risk at the wrist, hip, and other cortical-dominant sites. The effect operates additively: two copies of G confer the most risk, one copy intermediate risk, and AA (no G) offers the best genetic protection.

For GG individuals, building and protecting cortical bone requires active intervention. The two most evidence-backed strategies are ensuring adequate calcium (1,000–1,200 mg/day) and vitamin D (supporting levels of 30–60 ng/mL), combined with mechanical loading via weight-bearing exercise, which stimulates periosteal bone apposition — the cortical-specific growth mechanism most relevant to WNT16 function. For those under 30, the priority is maximizing peak bone mass; for those older, minimizing cortical bone loss rate.

The interaction with underweight status (BMI interaction p = 0.0148) is clinically meaningful: GG individuals who are underweight face compounded risk. Low body weight accelerates cortical bone loss through reduced mechanical load and lower estrogen/androgen levels — exactly the pathways WNT16 impairment already compromises.

Interactions

Rs2908004 is in high linkage disequilibrium with rs3801387 (intronic, regulatory) and rs2707466 (another missense variant, Thr>Ile), which together form a WNT16 haplotype block spanning 7q31.311010 WNT16 haplotype block spanning 7q31.31. These variants partially tag each other, but rs2908004 captures the coding-level impact directly. The Zheng 2012 analysis showed both missense variants contributing to the cortical bone signal, with rs2707466 showing the stronger cortical thickness association and rs2908004 stronger for forearm BMD.

WNT16 function intersects with the broader WNT signaling architecture including LRP5 (co-receptor) and SOST (sclerostin — a WNT inhibitor). Individuals with risk variants in both WNT16 and LRP5 may face compounded cortical bone deficits. Separately, the BMI interaction (Wu et al. 2022) suggests WNT16 genotype modifies how body composition affects bone health — providing a precision lens on dietary and exercise counseling that goes beyond standard advice.

Nutrient Interactions

calcium increased_need
vitamin D increased_need

Genotype Interpretations

What each possible genotype means for this variant.

AA Protective Variant Beneficial

No G-allele copies — best cortical bone protection from this variant

The AA genotype at rs2908004 means your WNT16 protein is the ancestral Gly82 form — the configuration without the bulky arginine substitution that disrupts the cysteine-rich domain. Your osteoblast-secreted WNT16 is positioned to efficiently suppress osteoclast formation and maintain cortical thickness. The Zheng 2012 GWAS meta-analysis quantified the effect of each G allele as −0.16 SD for forearm BMD; with zero G alleles, you carry the best-case genetic starting point for cortical bone density at this locus.

This does not make you immune to osteoporosis — bone health depends on calcium, vitamin D, mechanical loading, hormonal status, and many other genetic factors. But at this particular locus, your genetics are working in your favor. Standard bone health recommendations apply, and no WNT16-specific intervention is needed based on this variant alone.

AG One Risk Copy Intermediate

One G allele — moderately reduced cortical bone protection

The heterozygous AG state means one of your two WNT16 gene copies produces the Gly82Arg protein (with reduced signaling capacity) and one produces the normal Gly82 form. In bone tissue, both copies contribute to the pool of secreted WNT16 available to suppress osteoclastogenesis, so you retain partial protection.

The García-Ibarbia 2013 study showed that WNT16 missense variants exhibit additive effects on femoral neck BMD — the heterozygote effect is intermediate between both homozygotes. Practically, this means your cortical bone trajectory is slightly less favorable than AA but you don't carry the pronounced risk associated with GG. Supporting the two key inputs to cortical bone formation — calcium/vitamin D adequacy and mechanical loading — is particularly worthwhile given the moderate genetic disadvantage at this locus.

The interaction between rs2908004 and underweight status documented in the Taiwan Biobank study is relevant here too: if you are underweight (BMI < 18.5), the combination may amplify your cortical bone risk beyond what either factor alone would predict.

GG Two Risk Copies High Risk

Two G alleles — highest cortical bone risk from this variant

The GG genotype means both copies of WNT16 carry the Gly82Arg substitution — a bulky arginine replacing the structurally critical glycine at position 82 within the cysteine-rich domain of the WNT16 protein. With both copies producing the Arg82 form, WNT16's ability to suppress osteoclast differentiation and upregulate osteoprotegerin is maximally impaired. The consequences play out over decades: starting from peak bone mass acquisition in young adulthood through age-related bone loss, each year with reduced WNT16 signaling contributes cumulatively to thinner cortical bone.

The effect size quantified in Zheng 2012 — −0.16 SD per G allele — implies approximately −0.32 SD for the GG genotype compared to AA. Over a population, a ~0.3 SD reduction in BMD translates meaningfully into earlier crossing of the osteoporosis diagnostic threshold and higher fracture incidence. The García-Ibarbia 2013 data showed the GG-equivalent genotype was significantly overrepresented in hip fracture patients under age 80.

The documented interaction with underweight status (Taiwan Biobank, p = 0.0148) is especially important: GG individuals who are underweight faced a 7.66-fold higher osteoporosis risk in that cohort — a combination of genetic predisposition and reduced skeletal mechanical loading that demands attention if BMI is low.

Early peak bone mass optimization (under age 30) is the highest-leverage intervention. Between ages 20–30, bone accrual can still offset some genetic disadvantage. After peak bone mass, the window shifts to minimizing loss rate — where calcium, vitamin D, and mechanical loading remain the primary modifiable levers.